Nav: Home

Belgian researchers discover a novel method to block immunosuppression in cancer

October 25, 2018

Belgian research groups from the UCLouvain and WELBIO, VIB and Ghent University, and the biotechnology company argenx elucidated the three-dimensional structure of an assembly of proteins operating on cells that dampen immune responses. They also discovered how an antibody can block this assembly and the immunosuppression it induces downstream. Such an antibody could serve to stimulate immunity against tumor cells in cancer patients, triggering the destruction of their tumors by immune cells. The study is published in the authoritative journal Science.

Immunosuppression through a cascade of interactions

Tregs (regulatory T lymphocytes) are immunosuppressive cells that normally counterbalance excessive immune reactions to prevent autoimmune diseases. But in cancer patients, they play deleterious roles by tempering immune reactions against tumor cells. Tregs induce their effects by producing a protein messenger called TGF-beta. This messenger transmits inhibitory signals to immune cells in the immediate vicinity, notably those that are supposed to destroy tumors in cancer patients.

The way Tregs produce TGF-beta is complex and finely regulated, because TGF-beta is very potent and must be kept under tight control. Three years ago, Prof. Sophie Lucas and her team at the de Duve Institute of the UCLouvain discovered that TGF-beta is released by Tregs from a protein called GARP, present on the Treg surface. In collaboration with argenx, her team also discovered that it was possible to block the release of TGF-beta from GARP with specific antibodies, which were rare and difficult to obtain. The next thing to find out was how GARP regulates the production of the TGF-beta messenger and how antibodies actually block its release.

The molecular mechanisms elucidated

To address these questions, Sophie Lucas and argenx initiated a collaboration with the team of Prof. Savvas Savvides at the VIB-UGent Center for Inflammation Research, to resolve the three-dimensional structure of the protein assembly made of GARP and TGF-beta. The researchers used X-ray crystallography, a method that has been used to study the structure of molecules for more than a century and that is still being developed for the study of biological macromolecules at atomic resolution. However, they were confronted with the practical problem that they could not readily obtain crystals of the GARP and TGF-beta complex. Via a highly collaborative effort spearheaded by Dr. Stéphanie Lienart (UCLouvain) and Dr. Romain Merceron (VIB - Ghent University), the two teams decided to use a blocking antibody to stabilize the structure - a successful approach that not only helped to generate suitable crystals for structure determination, but also provided details about how a therapeutic antibody might function.

Prof. Savvas Savvides (VIB-UGent): "We discovered that GARP resembles a horseshoe that is straddled by TGF-beta. The two molecules are so intricately assembled that TGF-beta itself contributes to the structure of the GARP horseshoe. The antibody fragment sticks to both GARP and TGF-beta in the assembly. It appears to glue the two molecules to one another, ensuring that when other molecules pull on one part of the assembly, the small, active part of TGF-beta is not released, and is thus prevented from conveying its inhibitory message."

Prof. Sophie Lucas (de Duve Institute at the UCLouvain): "Visualization of this large molecular assembly illustrates the feasibility of blocking TGF-beta activity emanating from a precisely defined and restricted cellular source, such as the surface of Tregs. This can lead to the design of exquisitely specific approaches to treat various diseases associated with altered TGF-beta or Treg activity, most notably for the immunotherapy of cancer."
-end-
Publication

Structural basis of latent TGF-β1 presentation and activation by GARP on human regulatory T cells, Liénart, Merceron et al., Science 2018

doi: 10.1126/science.aau2909

Questions from patients

A breakthrough in research is not the same as a breakthrough in medicine. The realizations of VIB researchers can form the basis of new therapies, but the development path still takes years. This can raise a lot of questions. That is why we ask you to please refer questions in your report or article to the email address that VIB makes available for this purpose: patienteninfo@vib.be. Everyone can submit questions concerning this and other medically-oriented research directly to VIB via this address.

Financing

WELBIO, FNRS, ERC consolidator grant under the European Union's Horizon H2020 research and innovation program (grant n° 682818), VIB and Ghent University

VIB (the Flanders Institute for Biotechnology)

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.